Regeneron shares flat as investors await key fianlimab trial results

3 articles · Updated · Barron's · Apr 29

Regeneron reported adjusted Q1 earnings of $9.47 per share on $3.61 billion revenue, both above expectations, while shares slipped 0.4% to $729 in premarket trading.
Dupixent sales surged 33% to $4.9 billion, but standard Eylea sales fell 10% as biosimilar competition looms. R&D spending rose to $1.54 billion, with full-year guidance reiterated.
Despite strong financials, investor focus remains on upcoming Phase 3 fianlimab data for metastatic melanoma. Regeneron recently struck a drug pricing deal with the Trump administration and expanded business development partnerships.

Can Regeneron's huge R&D bet outrun its looming Eylea patent cliff?

Why is Regeneron's stock called 'undervalued' despite record revenue and a breakthrough gene therapy?

Will Regeneron's drug pricing deal with the U.S. government become the new blueprint for big pharma?

Regeneron's new gene therapy is free, but who ultimately pays for this medical breakthrough?

Regeneron is using 300 million patient records for AI. What does this mean for your medical data?

Eylea HD sales surged 52% as standard Eylea fell. Is this a successful defense or a temporary fix?